Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Lymphoma, T-Cell, Peripheral 1Esophageal Squamous Cell Carcinoma 1

Interventions

Cisplatin 14Paclitaxel 12pembrolizumab 9Fluorouracil 7Radiotherapy 6Irinotecan 5Esophagectomy 5tislelizumab 4Oxaliplatin 4Leucovorin 4Drug Therapy 4Carboplatin 4toripalimab 3Levoleucovorin 3Docetaxel 3Capecitabine 3camrelizumab 2Taxes 2Radiation 2Nivolumab 2Injections 2130-nm albumin-bound paclitaxel 2spartalizumab 1sintilimab 1palbociclib 1nimotuzumab 1nazartinib 1lenvatinib 1ivarmacitinib 1futibatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esophageal Squamous Cell Carcinoma × ivarmacitinib × 90 days × Clear all
NCT07505186 2026-04-01

Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Not yet recruiting
45 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡